In a report released yesterday, Stephen Baxter from Wells Fargo maintained a Hold rating on Cardinal Health (CAH – Research Report), with a ...
Morgan Stanley analyst Erin Wright maintained a Buy rating on Cardinal Health (CAH – Research Report) today and set a price target of $136.00.
Cardinal Health, Inc. CAH is scheduled to report fiscal second-quarter 2025 results on Jan. 30, before the opening bell. In ...
In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe ...
Stocks to Buy or Sell. In this article, we are going to take a look at where Cardinal Health, Inc. (NYSE:CAH) stands against ...
Cardinal Health gets downgraded to a hold ... A key risk in this segment is that of regulatory and legal costs involving medical products and drugs. From its profile, what this firm is known ...
Jim Cramer in a latest program on CNBC reminded viewers about the Trump playbook in the story market and said that he never ...
About Cardinal Health Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home ...
The company said the new DC will support its at-Home Solutions business and improve the delivery of medical supplies to ...
Some readers see legalization as a matter of personal liberty, others see tax revenue. Still others see more impaired drivers ...